Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02422290 · ClinicalTrials.gov registry record · Phase 1
Ketamine Treatment for Pediatric-Refractory Obsessive-Compulsive Disorder (OCD)
A Phase 1 study, sponsored by New York State Psychiatric Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT02422290 is a Phase 1 study that has completed, run by New York State Psychiatric Institute. The registered enrollment target is 5 participants.
The verdict
NCT02422290, a Phase 1 study, has completed, sponsored by New York State Psychiatric Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
This pilot study is proposed to determine the acceptability, feasibility and potential efficacy of ketamine, a medication that modulates glutamate in the brain, as a rapid treatment for obsessive-compulsive disorder (OCD) symptoms in adolescents and young adults with OCD. This study will recruit 6 youth (ages 14-22) who are diagnosed with clinically significant OCD and have failed at least one adequate trial of a Serotonin Reuptake Inhibitor (SRI) medication and a course of Cognitive-Behavioral Therapy (CBT) (unless unable to access or tolerate) for OCD in the past. Participants will receive a single infusion of intravenous ketamine and be assessed at regular intervals post-infusion for up to 14 days. At the end of the 14-day treatment phase, all participants will be offered three months of open treatment for OCD with medication and/or CBT.
Interventions
- DRUG Ketamine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2015-03 |
| Est. Completion | 2020-07-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02422290
The ClinicalTrials.gov registry entry for NCT02422290 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New York State Psychiatric Institute, which has 364 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ketamine is the first listed.
NCT02422290 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02422290 about?
NCT02422290 is a clinical study titled "Ketamine Treatment for Pediatric-Refractory Obsessive-Compulsive Disorder (OCD)". This pilot study is proposed to determine the acceptability, feasibility and potential efficacy of ketamine, a medication that modulates glutamate in the brain, as a rapid treatment for obsessive-compulsive disorder (OCD) symptoms in adolescents and young adults with OCD. This study will recruit 6 y...
What is the current status of trial NCT02422290?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2015-03. Estimated completion is 2020-07-31.
What interventions are being tested in trial NCT02422290?
The interventions under investigation include: Ketamine (DRUG).
Who is sponsoring clinical trial NCT02422290?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.